Citigroup
FDMT icon

Citigroup’s 4D Molecular Therapeutics FDMT Stock Holding History

Citigroup’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244K Buy
26,180
+13,521
+107% +$118K ﹤0.01% 3921
2025
Q4 		$94.9K Buy
12,659
+9,164
+262% +$93K ﹤0.01% 4347
2025
Q3 		$30.4K Sell
3,495
-19,301
-85% -$115K ﹤0.01% 4656
2025
Q2 		$84.6K Sell
22,796
-62,284
-73% -$219K ﹤0.01% 4492
2025
Q1 		$275K Sell
85,080
-8,541
-9% -$40.2K ﹤0.01% 4007
2024
Q4 		$521K Buy
93,621
+3,219
+4% +$25.3K ﹤0.01% 3791
2024
Q3 		$977K Buy
90,402
+7,592
+9% +$126K ﹤0.01% 3280
2024
Q2 		$1.74M Sell
82,810
-70,474
-46% -$1.77M ﹤0.01% 2457
2024
Q1 		$4.88M Buy
153,284
+111,976
+271% +$2.86M ﹤0.01% 1721
2023
Q4 		$837K Sell
41,308
-13,391
-24% -$176K ﹤0.01% 2979
2023
Q3 		$696K Sell
54,699
-3,458
-6% -$57.8K ﹤0.01% 2799
2023
Q2 		$1.05M Sell
58,157
-53,521
-48% -$985K ﹤0.01% 2813
2023
Q1 		$1.92M Buy
111,678
+85,862
+333% +$1.67M ﹤0.01% 2050
2022
Q4 		$573K Buy
25,816
+15,922
+161% +$246K ﹤0.01% 3067
2022
Q3 		$80K Sell
9,894
-2,343
-19% -$21.2K ﹤0.01% 4197
2022
Q2 		$85K Sell
12,237
-16,358
-57% -$159K ﹤0.01% 4296
2022
Q1 		$432K Sell
28,595
-54,577
-66% -$857K ﹤0.01% 3611
2021
Q4 		$1.82M Buy
83,172
+80,369
+2,867% +$1.97M ﹤0.01% 2697
2021
Q3 		$76K Buy
2,803
+1,218
+77% +$34.7K ﹤0.01% 4525
2021
Q2 		$38K Buy
1,585
+217
+16% +$6.64K ﹤0.01% 4942
2021
Q1 		$59K Buy
+1,368
New +$60.6K ﹤0.01% 4609

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citigroup's FDMT Position: Q1 2026 in Review

Citigroup increased its 4D Molecular Therapeutics (FDMT) stake by 107% in Q1 2026, buying an estimated $118K and bringing the position to 26,180 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #3921.

Citigroup first reported a position in FDMT in Q1 2021 and has held it in 21 quarters since. The position peaked at $4.88M in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Citigroup held 26,180 shares of 4D Molecular Therapeutics worth $244K as of Q1 2026.
  • Citigroup bought 13,521 4D Molecular Therapeutics shares in Q1 2026, an estimated $118K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3921 holding.
  • Citigroup first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citigroup's 4D Molecular Therapeutics position peaked at $4.88M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.